The cell and gene therapy market size has grown exponentially in recent years. It will grow from $12.01 billion in 2024 to $15.48 billion in 2025 at a compound annual growth rate (CAGR) of 28.9%. The growth in the historic period can be attributed to an increase in investments in cell and gene therapies, growth in research and development, advances in cancer drug discovery, rise in public-private partnerships, strong economic growth in emerging markets, increased healthcare expenditure, and rising in pharmaceutical R&D expenditure.
The cell and gene therapy market size is expected to see rapid growth in the next few years. It will grow to $29.15 billion in 2029 at a compound annual growth rate (CAGR) of 17.1%. The growth in the forecast period can be attributed to the increasing prevalence of cancer and chronic diseases, rising geriatric population, rising geriatric population, rising focus on cell and gene therapy, and rise in healthcare expenditure. Major trends in the forecast period include focusing on advanced therapies such as chimeric antigen receptor (CAR) T-cell therapy, concentrating on undertaking various research initiatives and attaining funding, carrying out strategic collaborations to integrate advanced technologies, concentrating on developing gene or genome editing tools especially CRISPR, partnering or acquiring competitor companies, increasing the number of pipeline studies to develop cell and gene therapies, and investing in manufacturing facilities expansion.
Consistent investment and consolidation in cell and gene therapies have fueled the growth of the cell and gene therapy (CGT) market. Recognizing the market's potential, 16 of the 20 largest biopharmaceutical companies by revenue have integrated CGT products into their portfolios. For example, in 2023, the BioIndustry Association (BIA), a UK-based organization representing the life sciences and biotech sectors, reported that UK cell and gene therapy companies captured over 55% of the venture capital funding secured by European firms. Overall, the UK accounts for approximately one-third of all European VC investments in life sciences, underscoring the robust position of its cell and gene therapy industry. The steady investment and consolidation in CGT production capacity have led to an increase in production capabilities, further contributing to market growth. For instance, in October 2024, Purespring Therapeutics, a UK-based biotechnology firm, secured $105 million in funding to support the development of gene therapies for kidney diseases, including a phase 1/2 trial for an experimental treatment of immunoglobulin A nephropathy (IgAN). Purespring employs adeno-associated viruses (AAVs) to deliver its gene therapies into the body.
The burgeoning number of ongoing clinical trials stands as a driving force propelling the cell and gene therapy market forward. Clinical trials serve as pivotal research studies involving human participants to assess the safety and efficacy of new medical treatments, interventions, or diagnostic procedures. In the realm of cell and gene therapy, these trials play an integral role in advancing these innovative therapies by providing a controlled environment to evaluate their safety and efficacy. As evidenced by data from ClinicalTrials.gov, a division of the National Institutes of Health (NIH), the number of registered studies increased significantly from 437,523 in 2022 to 468,457 across all 50 states of the United States and spanning 221 countries by October 2023. Notably, a considerable portion of these studies - 143,613 (31% of the total) - are conducted solely within the U.S., while 251,159 studies (54% of the total) are conducted in non-U.S. locations. This escalating number of ongoing clinical trials signifies a driving force behind the growth trajectory of the cell and gene therapy market.
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a pivotal driver shaping the landscape of the cell and gene therapy (CGT) market. This innovative therapy combines elements of both cell and gene therapy by utilizing T cells obtained from a patient's blood, which are then genetically modified to produce specialized receptors known as chimeric antigen receptors (CARs) on their surface. These engineered T cells, equipped with modified receptors, are reintroduced into the patient's system. The modified receptors on the T cells enable them to effectively target and bind to specific surface antigens present on cancer cells, ultimately leading to the destruction of tumor cells within patients. A notable example occurred in June 2022 when Bristol-Myers Squibb Company, a US-based pharmaceutical firm, received approval from the United States Food and Drug Administration (US FDA) for Breyanzi, a CAR T cell therapy designed for treating adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma. Breyanzi stands out as a distinct CAR T cell therapy engineered from a patient's own T cells, collected and genetically reengineered into CAR T cells, subsequently administered via infusion as a one-time treatment.
Major companies operating within the cell and gene therapy market are intensifying their focus on introducing agnostic systems to gain a competitive edge. Agnostic systems encompass platforms integrated with a diverse array of cell and gene therapy (CGT) software platforms, as well as biopharmaceutical or provider-facing platforms. For instance, in April 2023, AmerisourceBergen, a US-based healthcare company, unveiled the Cell and Gene Therapy Integration Hub - a newly launched platform-agnostic system. This innovative system aims to enhance connectivity throughout the cell and gene therapy treatment journey, elevating the overall patient and provider experience. Powered by the company's customer relationship management system, the hub is designed to expedite the benefits investigation process, offer real-time insights into therapy development and transportation status, and assist in streamlining patient support coordination.
In January 2024, Kyowa Kirin Co., Ltd., a pharmaceutical company based in Japan that develops and markets medications to enhance global human health and well-being, acquired Orchard Therapeutics for an undisclosed amount. Through this acquisition, Kyowa Kirin Co., Ltd. intends to bolster its capabilities in creating innovative gene therapies for rare diseases, broaden its therapeutic portfolio, and meet unmet medical needs. Orchard Therapeutics plc is a biotechnology company located in the UK that focuses on developing cutting-edge cell and gene therapies.
Major companies operating in the cell and gene therapy market include Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Biocon, Cipla, Stempeutics Research Pvt. Ltd., EdiGene Inc., Immunochina, Takara Bio, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Oxford Biomedica plc, Santen Pharmaceutical Co., Therapeutic Innovation Australia, Merck, GenScript, Cellular Biomedicine Group, GE Healthcare, inStem, Lonza, Nikon CeLL innovation Co. Ltd., Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Oxford BioTherapeutics, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca.
North America was the largest region in the cell and gene therapy market in 2024. The regions covered in the cell and gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell and gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
Gene therapy involves delivering genetic material, typically through a carrier or vector, with the gene being taken up by the appropriate body cells. Cell therapy, on the other hand, entails introducing cells into the patient to restore proper function. Some procedures combine both cell and gene therapy.
The primary product categories in cell and gene therapies are cell therapy and gene therapy. Gene therapy in medicine focuses on modifying the genetic material of cells for therapeutic effects or disease healing by repairing damaged genetic material. Applications span oncology, dermatology, musculoskeletal treatments, and others, with utilization across sectors such as hospitals, ambulatory surgical centers, cancer care centers, wound care centers, and more.
The cell and gene therapy market research report is one of a series of new reports that provides cell and gene therapy market statistics, including global market size, regional shares, competitors with a cell and gene therapy market share, detailed cell and gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy industry. This cell and gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The cell and gene therapy market includes revenues earned by entities treating cancer, cystic fibrosis, heart disease, diabetes, haemophilia, and AIDS. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The cell and gene therapy market size is expected to see rapid growth in the next few years. It will grow to $29.15 billion in 2029 at a compound annual growth rate (CAGR) of 17.1%. The growth in the forecast period can be attributed to the increasing prevalence of cancer and chronic diseases, rising geriatric population, rising geriatric population, rising focus on cell and gene therapy, and rise in healthcare expenditure. Major trends in the forecast period include focusing on advanced therapies such as chimeric antigen receptor (CAR) T-cell therapy, concentrating on undertaking various research initiatives and attaining funding, carrying out strategic collaborations to integrate advanced technologies, concentrating on developing gene or genome editing tools especially CRISPR, partnering or acquiring competitor companies, increasing the number of pipeline studies to develop cell and gene therapies, and investing in manufacturing facilities expansion.
Consistent investment and consolidation in cell and gene therapies have fueled the growth of the cell and gene therapy (CGT) market. Recognizing the market's potential, 16 of the 20 largest biopharmaceutical companies by revenue have integrated CGT products into their portfolios. For example, in 2023, the BioIndustry Association (BIA), a UK-based organization representing the life sciences and biotech sectors, reported that UK cell and gene therapy companies captured over 55% of the venture capital funding secured by European firms. Overall, the UK accounts for approximately one-third of all European VC investments in life sciences, underscoring the robust position of its cell and gene therapy industry. The steady investment and consolidation in CGT production capacity have led to an increase in production capabilities, further contributing to market growth. For instance, in October 2024, Purespring Therapeutics, a UK-based biotechnology firm, secured $105 million in funding to support the development of gene therapies for kidney diseases, including a phase 1/2 trial for an experimental treatment of immunoglobulin A nephropathy (IgAN). Purespring employs adeno-associated viruses (AAVs) to deliver its gene therapies into the body.
The burgeoning number of ongoing clinical trials stands as a driving force propelling the cell and gene therapy market forward. Clinical trials serve as pivotal research studies involving human participants to assess the safety and efficacy of new medical treatments, interventions, or diagnostic procedures. In the realm of cell and gene therapy, these trials play an integral role in advancing these innovative therapies by providing a controlled environment to evaluate their safety and efficacy. As evidenced by data from ClinicalTrials.gov, a division of the National Institutes of Health (NIH), the number of registered studies increased significantly from 437,523 in 2022 to 468,457 across all 50 states of the United States and spanning 221 countries by October 2023. Notably, a considerable portion of these studies - 143,613 (31% of the total) - are conducted solely within the U.S., while 251,159 studies (54% of the total) are conducted in non-U.S. locations. This escalating number of ongoing clinical trials signifies a driving force behind the growth trajectory of the cell and gene therapy market.
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a pivotal driver shaping the landscape of the cell and gene therapy (CGT) market. This innovative therapy combines elements of both cell and gene therapy by utilizing T cells obtained from a patient's blood, which are then genetically modified to produce specialized receptors known as chimeric antigen receptors (CARs) on their surface. These engineered T cells, equipped with modified receptors, are reintroduced into the patient's system. The modified receptors on the T cells enable them to effectively target and bind to specific surface antigens present on cancer cells, ultimately leading to the destruction of tumor cells within patients. A notable example occurred in June 2022 when Bristol-Myers Squibb Company, a US-based pharmaceutical firm, received approval from the United States Food and Drug Administration (US FDA) for Breyanzi, a CAR T cell therapy designed for treating adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma. Breyanzi stands out as a distinct CAR T cell therapy engineered from a patient's own T cells, collected and genetically reengineered into CAR T cells, subsequently administered via infusion as a one-time treatment.
Major companies operating within the cell and gene therapy market are intensifying their focus on introducing agnostic systems to gain a competitive edge. Agnostic systems encompass platforms integrated with a diverse array of cell and gene therapy (CGT) software platforms, as well as biopharmaceutical or provider-facing platforms. For instance, in April 2023, AmerisourceBergen, a US-based healthcare company, unveiled the Cell and Gene Therapy Integration Hub - a newly launched platform-agnostic system. This innovative system aims to enhance connectivity throughout the cell and gene therapy treatment journey, elevating the overall patient and provider experience. Powered by the company's customer relationship management system, the hub is designed to expedite the benefits investigation process, offer real-time insights into therapy development and transportation status, and assist in streamlining patient support coordination.
In January 2024, Kyowa Kirin Co., Ltd., a pharmaceutical company based in Japan that develops and markets medications to enhance global human health and well-being, acquired Orchard Therapeutics for an undisclosed amount. Through this acquisition, Kyowa Kirin Co., Ltd. intends to bolster its capabilities in creating innovative gene therapies for rare diseases, broaden its therapeutic portfolio, and meet unmet medical needs. Orchard Therapeutics plc is a biotechnology company located in the UK that focuses on developing cutting-edge cell and gene therapies.
Major companies operating in the cell and gene therapy market include Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Biocon, Cipla, Stempeutics Research Pvt. Ltd., EdiGene Inc., Immunochina, Takara Bio, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Oxford Biomedica plc, Santen Pharmaceutical Co., Therapeutic Innovation Australia, Merck, GenScript, Cellular Biomedicine Group, GE Healthcare, inStem, Lonza, Nikon CeLL innovation Co. Ltd., Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Oxford BioTherapeutics, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca.
North America was the largest region in the cell and gene therapy market in 2024. The regions covered in the cell and gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell and gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
Gene therapy involves delivering genetic material, typically through a carrier or vector, with the gene being taken up by the appropriate body cells. Cell therapy, on the other hand, entails introducing cells into the patient to restore proper function. Some procedures combine both cell and gene therapy.
The primary product categories in cell and gene therapies are cell therapy and gene therapy. Gene therapy in medicine focuses on modifying the genetic material of cells for therapeutic effects or disease healing by repairing damaged genetic material. Applications span oncology, dermatology, musculoskeletal treatments, and others, with utilization across sectors such as hospitals, ambulatory surgical centers, cancer care centers, wound care centers, and more.
The cell and gene therapy market research report is one of a series of new reports that provides cell and gene therapy market statistics, including global market size, regional shares, competitors with a cell and gene therapy market share, detailed cell and gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy industry. This cell and gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The cell and gene therapy market includes revenues earned by entities treating cancer, cystic fibrosis, heart disease, diabetes, haemophilia, and AIDS. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Cell and Gene Therapy Market Characteristics3. Cell and Gene Therapy Market Trends and Strategies4. Cell and Gene Therapy Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Cell and Gene Therapy Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Cell and Gene Therapy Market34. Recent Developments in the Cell and Gene Therapy Market
5. Global Cell and Gene Therapy Growth Analysis and Strategic Analysis Framework
6. Cell and Gene Therapy Market Segmentation
7. Cell and Gene Therapy Market Regional and Country Analysis
8. Asia-Pacific Cell and Gene Therapy Market
9. China Cell and Gene Therapy Market
10. India Cell and Gene Therapy Market
11. Japan Cell and Gene Therapy Market
12. Australia Cell and Gene Therapy Market
13. Indonesia Cell and Gene Therapy Market
14. South Korea Cell and Gene Therapy Market
15. Western Europe Cell and Gene Therapy Market
16. UK Cell and Gene Therapy Market
17. Germany Cell and Gene Therapy Market
18. France Cell and Gene Therapy Market
19. Italy Cell and Gene Therapy Market
20. Spain Cell and Gene Therapy Market
21. Eastern Europe Cell and Gene Therapy Market
22. Russia Cell and Gene Therapy Market
23. North America Cell and Gene Therapy Market
24. USA Cell and Gene Therapy Market
25. Canada Cell and Gene Therapy Market
26. South America Cell and Gene Therapy Market
27. Brazil Cell and Gene Therapy Market
28. Middle East Cell and Gene Therapy Market
29. Africa Cell and Gene Therapy Market
30. Cell and Gene Therapy Market Competitive Landscape and Company Profiles
31. Cell and Gene Therapy Market Other Major and Innovative Companies
35. Cell and Gene Therapy Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Cell and Gene Therapy Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on cell and gene therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cell and gene therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cell and gene therapy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product: Cell Therapy, Gene Therapy2) By Application: Oncology, Neurological Disorders, Other Applications
3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users
Subsegments:
1) By Cell Therapy: Autologous Cell Therapy; Allogeneic Cell Therapy; Stem Cell Therapy; CAR-T Cell Therapy2) By Gene Therapy: Viral Vector-Based Gene Therapy; Non-Viral Vector-Based Gene Therapy; Genome Editing Technologies; Antisense Oligonucleotide Therapy
Key Companies Mentioned: Biogen Inc.; Novartis AG; Gilead Sciences; Ionis Pharmaceuticals Inc.; Alnylam Pharmaceuticals Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Biogen Inc.
- Novartis AG
- Gilead Sciences
- Ionis Pharmaceuticals Inc.
- Alnylam Pharmaceuticals Inc.
- ArrowHead Pharmaceuticals Inc.
- Spark Therapeutics
- Bluebird Bio Inc.
- RegenexBio
- Mesoblast Limited
- Biocon
- Cipla
- Stempeutics Research Pvt. Ltd.
- EdiGene Inc.
- Immunochina
- Takara Bio
- Daiichi Sankyo Company
- Ultragenyx Pharmaceutical Inc
- Mitsubishi Tanabe Pharma
- Oxford Biomedica plc
- Santen Pharmaceutical Co.
- Therapeutic Innovation Australia
- Merck
- GenScript
- Cellular Biomedicine Group
- GE Healthcare
- inStem
- Lonza
- Nikon CeLL innovation Co. Ltd.
- Bristol-Myers Squibb
- Amgen
- Pfizer
- Kite Pharma
- Oxford BioTherapeutics
- Freeline Therapeutics
- PsiOxus Therapeutics
- Herantis Pharma Plc
- AstraZeneca
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | March 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 15.48 Billion |
| Forecasted Market Value ( USD | $ 29.15 Billion |
| Compound Annual Growth Rate | 17.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 38 |
